116 completed, 27 terminated, 16 recruiting, 8 withdrawn. 182 Phase 3, 22 Phase 2.
Follow Seizures: new trials by email Literature Review of Seizures trials Research Report on Seizures
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE" Anakinra, Tocilizumab, Standard medical treatment - New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus | Phase 3 | Not yet recruiting | Yale University | 438 | 2026-12-01 | 2026-08-19 |
| Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures RAP-219, Placebo - Focal Seizure, Epilepsy | Phase 3 | Recruiting | Rapport Therapeutics Inc. | 312 | 2026-09-01 | 2026-11-12 |
| Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1 RAP-219, Placebo - Focal Seizure, Epilepsy | Phase 3 | Recruiting | Rapport Therapeutics Inc. | 333 | 2026-06-05 | 2026-11-12 |
| Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT) Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET), Levetiracetam (LEV) (60 mg/Kg) + 3 mg/kg Ketamine (KET), Levetiracetam (LEV) (60 mg/Kg) - Status Epilepticus | Phase 3 | Recruiting | University of Virginia | 770 | 2026-03-06 | 2026-09-17 |
| Targeted Hypothermia Versus Targeted Normothermia After Convulsive Refractory Status Epilepticus Targeted Hypothermia - Convulsive Refractory Status Epilepticus, Status Epilepticus | Phase 3 | Not yet recruiting | Versailles Hospital | 466 | 2026-03-01 | 2026-02-10 |
| Levetiracetam Compared to Magnesium Sulfate for Prevention of Eclamptic Seizure Levetiracetam, magnesium sulfate - Severe Preeclampsia, Eclampsia Preeclampsia | Phase 3 | Not yet recruiting | Nebraska Methodist Health System | 1240 | 2026-01-01 | 2025-10-24 |
| LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome Levetiracetam 500mg, Placebo - Down Syndrome, Down Syndrome (DS) | Phase 3 | Recruiting | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 120 | 2025-12-22 | 2026-01-12 |
| Clinical Trial of Vormatrigine in Adult Patients With Epilepsy vormatrogine - Epilepsy, Tonic-Clonic, Focal Seizure | Phase 3 | Enrolling by invitation | Praxis Precision Medicines | 700 | 2025-10-27 | 2026-08-03 |
| A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety 1mg elsunersen, 0.5mg elsunersen - Epileptic Encephalopathy, SCN2A Encephalopathy | Phase 3 | Recruiting | Praxis Precision Medicines | 40 | 2025-08-13 | 2026-08-03 |
| Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK) Ketamine, Midazolam - Convulsive Status EPILEPTICUS | Phase 2 / Phase 3 | Recruiting | Sohag University | 668 | 2025-08-03 | 2025-08-05 |
| Ketamine and Levetiracetam as Second-line Antiseizure Medication for Status Epilepticus in Children Ketamine, Levetiracetam, Placebo - Generalized Convulsive Status Epilepticus | Phase 2 / Phase 3 | Recruiting | Sohag University | 124 | 2025-07-02 | 2025-07-03 |
| An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome Clemizole HCl, Placebo - Lennox Gastaut Syndrome | Phase 3 | Recruiting | Epygenix | 260 | 2025-04-09 | 2026-10-09 |
| Levetiracetam Prophylaxis in Brain Tumor Resection Pilot Levetiracetam, Placebo - Seizures, Brain Tumor | Phase 3 | Not yet recruiting | Hamilton Health Sciences Corporation | 70 | 2025-03-01 | 2024-10-23 |
| A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) LP352 - Developmental and Epileptic Encephalopathy | Phase 3 | Enrolling by invitation | Longboard Pharmaceuticals | 324 | 2025-02-12 | 2026-10-14 |
| Decreasing Postoperative Blood Loss and Seizures by Timing of Intravenous Tranexamic Acid 2 Pilot Trial Before CPB Tranexamic Acid, After CPB Tranexamic Acid, Before CPB Placebo - Bleeding, Surgical Blood Loss | Phase 3 | Unknown | Hamilton Health Sciences Corporation | 40 | 2025-01-01 | 2024-10-02 |
| Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1) 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks, Placebo - Focal Seizure | Phase 2 / Phase 3 | Completed | Praxis Precision Medicines | 255 | 2024-12-11 | 2026-08-10 |
| A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) LP352, Placebo - Developmental and Epileptic Encephalopathy | Phase 3 | Active not recruiting | Longboard Pharmaceuticals | 367 | 2024-11-11 | 2026-09-15 |
| A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) LP352, Placebo - Dravet Syndrome | Phase 3 | Active not recruiting | Longboard Pharmaceuticals | 108 | 2024-09-25 | 2026-10-27 |
| Short Versus Long-term Levetiracetam in Brain Tumors Levetiracetam - Seizures, Brain Tumors | Phase 3 | Recruiting | Tata Memorial Centre | 604 | 2024-07-04 | 2026-02-13 |
| A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures BHV-7000, Placebo - Generalized Epilepsy | Phase 2 / Phase 3 | Terminated | Biohaven Therapeutics Ltd. | 27 | 2024-06-20 | 2026-03-24 |
Showing 20 of 182. Sign in to see all of them.
Epilepsy (109) · Epilepsies, Partial (35) · Status Epilepticus (27) · Epilepsies, Myoclonic (11) · Lennox Gastaut Syndrome (11) · Epilepsy, Complex Partial (8) · Epilepsy, Generalized (8) · Brain Diseases (7) · Drug Resistant Epilepsy (7) · Epilepsy, Tonic-Clonic (7) · Epilepsy, Idiopathic Generalized (5) · Tuberous Sclerosis (5) · Brain Neoplasms (4) · Central Nervous System Diseases (3)
Pathological Conditions, Signs and Symptoms (182) · Signs and Symptoms (182) · Nervous System Diseases (179) · Neurologic Manifestations (179) · Central Nervous System Diseases (131) · Brain Diseases (126) · Epileptic Syndromes (26) · Epilepsy, Generalized (20) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (18) · Epilepsy (18) · Genetic Diseases, Inborn (17) · Pathologic Processes (11) · Neoplasms (9) · Congenital Abnormalities (7)
Levetiracetam (25) · Topiramate (13) · Lorazepam (9) · S-2-O-carbamoyl-1-o-chlorophenyl-ethanol (9) · Ketamine (7) · Lacosamide (7) · Pregabalin (7) · Valproic Acid (7) · ezogabine (6) · Cannabidiol (5) · Fenfluramine (5) · Lamotrigine (5) · ganaxolone (5) · Carbamazepine (4) · Diazepam (4)
SK Life Science, Inc. (12) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (11) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (9) · GlaxoSmithKline (8) · Eisai Inc. (7) · UCB Pharma (6) · Marinus Pharmaceuticals (5) · Novartis Pharmaceuticals (5) · Sohag University (5) · Xenon Pharmaceuticals Inc. (5) · Jazz Pharmaceuticals (4) · Sumitomo Pharma America, Inc. (4) · UCB BIOSCIENCES, Inc. (4) · UCB Japan Co. Ltd. (4) · Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. (4)
United States (99) · Spain (41) · Italy (38) · Germany (37) · France (36) · Poland (36) · Australia (29) · Canada (29) · United Kingdom (27) · Belgium (25) · Japan (25) · Hungary (23) · Mexico (23) · Russia (21) · South Korea (20)
David Squillacote, M.D. (3) · Abdelrahim A Sadek, MD, PhD (2) · Amit Ray, MD (2) · Andre Lamy, MD (2) · Eric H Kossoff, MD (2) · Hiroki Takano (2) · James Chamberlain, MD (2)
PMID 37059702, PMID 23663001, PMID 25823975, PMID 25878175, PMID 33825230, PMID 34768178, PMID 34870321, PMID 35305920, PMID 19327967, PMID 19863578, PMID 22512894, PMID 29363050, PMID 30232735, PMID 33540241, PMID 34957550, PMID 10227614, PMID 10371538, PMID 10768306, PMID 10768307, PMID 12552030, PMID 12690085, PMID 15072107, PMID 15349872, PMID 16698412, PMID 17625106, PMID 18285535, PMID 18480196, PMID 20089937, PMID 20200383, PMID 20633037, PMID 20878265, PMID 20937567, PMID 21275979, PMID 21320109, PMID 21673279, PMID 21889410, PMID 21917777, PMID 21956725, PMID 21967361, PMID 21967362, PMID 22054656, PMID 22335736, PMID 22372628, PMID 22396514, PMID 22506949, PMID 22516508, PMID 22517103, PMID 22633629, PMID 22708895, PMID 22843280
2014 (8), 2023 (4), 2015 (3), 2018 (2), 2008 (1), 2016 (1), 2017 (1), R01NS040808 (1), U01NS045803 (1), U01NS056975 (1), U01NS088034 (1), U01NS114042 (1)